{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+1+in+Part+A&page=2", "query": { "intervention": "Cohort 1 in Part A", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 1373, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+1+in+Part+A&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+1+in+Part+A&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T03:24:53.498Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05507515", "title": "A Phase 1 Study of ONO-2020 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "ONO-2020", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ono Pharmaceutical Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2022-07-29", "completion_date": "2023-12-24", "has_results": false, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05507515" }, { "nct_id": "NCT02817633", "title": "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "TSR-022", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "TSR-042", "type": "DRUG" }, { "name": "TSR-033", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 463, "start_date": "2016-07-08", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 64, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02817633" }, { "nct_id": "NCT01972776", "title": "A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COPD" ], "interventions": [ { "name": "QBM076", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "35 Years to 75 Years" }, "enrollment_count": 48, "start_date": "2013-11", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2016-03-24", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01972776" }, { "nct_id": "NCT05127226", "title": "HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Angelman Syndrome" ], "interventions": [ { "name": "ION582", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "0 Years to 50 Years" }, "enrollment_count": 71, "start_date": "2021-12-22", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 6, "location_summary": "San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Carrboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05127226" }, { "nct_id": "NCT05503264", "title": "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "NMDAR Autoimmune Encephalitis", "LGI1 Autoimmune Encephalitis" ], "interventions": [ { "name": "Satralizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 122, "start_date": "2022-09-27", "completion_date": "2028-12-14", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 17, "location_summary": "Birmingham, Alabama • La Jolla, California • Newport Beach, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05503264" }, { "nct_id": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Esophageal Adenocarcinoma", "Cholangiocarcinoma", "Gallbladder Carcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-09-15", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04430738" }, { "nct_id": "NCT04126031", "title": "Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gram-negative Bacterial Infection" ], "interventions": [ { "name": "Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3", "type": "DRUG" }, { "name": "Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "88 Days", "sex": "ALL", "summary": "0 Days to 88 Days" }, "enrollment_count": 48, "start_date": "2020-01-14", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2024-03-26", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04126031" }, { "nct_id": "NCT00451022", "title": "Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer", "Liver Cancer", "Breast Cancer", "Colon Cancer", "Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2004-09-13", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00451022" }, { "nct_id": "NCT05704361", "title": "A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "RO7121932 IV", "type": "DRUG" }, { "name": "RO7121932 SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 119, "start_date": "2021-08-11", "completion_date": "2027-07-08", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 2, "location_summary": "Stanford, California • New Haven, Connecticut", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05704361" }, { "nct_id": "NCT06193486", "title": "Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "MSGV1-PSCA-8T28Z", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2024-10-26", "completion_date": "2033-12-13", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-05T03:24:53.498Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06193486" } ] }